1. European Directorate for Quality in Medicines (EDQM). European pharmacopeia 6.8, monograph 2.9.18. Preparations for inhalations: Aerodynamic assessment of fine particles. Strasburg, EDQM 2010.
2. US Pharmacopeial Convention. United States Pharmacopeia 33/National Formulary 28, Chapter <601> Aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers. Rockville, MD, 2010.
3. Christopher D, Curry P, Doub W, Furnkranz K, Lavery M, Lin K, et al. Considerations for the development and practice of cascade impaction testing including a mass balance failure investigation tree. J Aerosol Med. 2003;16(3):235–47. doi: 10.1089/089426803769017604 .
4. Tougas TP, Christopher D, Mitchell JP, Strickland H, Wyka B, Van Oort M, et al. Improved quality control metrics for cascade impaction measurements of orally inhaled drug products (OIPs). AAPS PharmSciTech. 2009;10(4):1276–85. doi: 10.1208/s12249-009-9312-4 .
5. Mitchell JP, Morton RW, Nagel MW. The influence of body geometry on spacer performance: a case study. In: Dalby RN, Byron PR, Farr SJ, Peart J, editors. Respiratory drug delivery-VII. Raleigh, North Carolina, USA: Serentec Press; 2000. p. 539–41.